ProCE Banner Activity

Future Directions: Moving Checkpoint Inhibitors into Earlier NSCLC Settings

Slideset Download
Download this slideset to get up to date on clinical research being done to improve checkpoint inhibitor therapy for unresectable stage III NSCLC and to move it into resectable early-stage disease.

Released: November 08, 2018

Expiration: November 07, 2019

No longer available for credit.

Share

Faculty

Naiyer Rizvi

Naiyer Rizvi, MD

Professor of Medicine
Price Chair of Thoracic Translational Oncology

Director of Thoracic Oncology
Director of Immuno-Oncology
Columbia University Medical Center
New York, New York

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Naiyer Rizvi, MD

Professor of Medicine
Price Chair of Thoracic Translational Oncology

Director of Thoracic Oncology
Director of Immuno-Oncology
Columbia University Medical Center
New York, New York